SEC For	m 4 =ORM 4	1 L		STAT	ES	SE	CURI	TIE	S AND E	EXCHA	IGE CO	OMMIS	SION					
					ATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL			
Section 16	box if no longe . Form 4 or For may continue. 1(b).	STATEMENT OF CHANGES IN BENEFICIAL OWNEF Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											Estim	OMB Number: 3235-0 Estimated average burden hours per response:				
1. Name and Address of Reporting Person* GADICKE ANSBERT					2. Issuer Name and Ticker or Trading Symbol <u>iTeos Therapeutics, Inc.</u> [ITOS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner					
(Last) (First) (Middle C/O MPM CAPITAL					3. Date of Earliest Transaction (Month/Day/Year) 07/23/2020 Officer (give title below)										Other (s below)	pecify		
450 KENDALL STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02142													X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																		
		Tab	ole I - Non-	-Deriva	ative	e Seo	curities	s Ac	quired, D	isposed c	of, or Be	neficial	ly Owned	l				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					ear) E	2A. Deemed Execution Date if any (Month/Day/Yea		Code (Ins			ed (A) or tr. 3, 4 and	4 and Securities Beneficially Owned Fol		Form (D) or	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code V	Amount	(A) oi (D)	Price	Reported Transact (Instr. 3 a	ion(s)			Instr. 4)	
		-	Table II - D (e						uired, Dis s, options,				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\	ate, Tr Co	ransaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/	ate	7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Co	ode	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$19	07/23/2020			A		16,608		(1)	07/23/2030	Common Stock	16,608	\$0.00	0		D		

Explanation of Responses:

1. This stock option shall vest over 3 years, with 1/3 vesting on July 23, 2021 and thereafter in equal monthly installments over the next 24 months subject to the Reporting Person's continued service to the Issuer.

Remarks:

<u>/s/ Michel Detheux, as</u> <u>Attorney-in-Fact</u>

07/24/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.